Pemigatinib was approved in April 2020 for previously treated, unresectable locally advanced or metastatic CCA with FGFR2 rearrangements, based on phase 2 FIGHT 202 (NCT02924376). The gene discussed is FGFR2; the disease is cholangiocarcinoma.